CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo" or the "Company"), a clinical stage biotechnology company developing a novel platform of
READ MORE1 · Find the latest Evelo Biosciences, Inc. (EVLO) stock quote, history, news and other vital information to help you with your stock trading and investing.
READ MORECAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company''s lead product in inflammation, detailing its mechanism
READ MORECAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting
READ MOREAbout Evelo Biosciences Evelo Biosciences is a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects. The small intestine plays a central role in governing inflammation throughout the body.
READ MOREEvelo Biosciences. EVLO. it is news worth sharing. Castle Biosciences reported revenue of $23.5 million, slightly above the By Trefis Team Contributor. Oct 26, 2021.
READ MORECAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced updates to its clinical programs. "In the fourth cohort of the
READ MOREEvelo Biosciences Announces $25.5 Million Private Placement. CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving 11 months ago - GlobeNewsWire.
READ MOREQuarterly Filings. 0001694665-23-000182.pdf. 0001694665-23-000182.rtf. 0001694665-23-000182.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. The Investor Relations website contains information about Evelo Biosciences''s business for stockholders, potential investors, and financial analysts.
READ MORECAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company
READ MOREEvelo Biosciences, a microbiome company launched by Flagship, shuts down. E velo Biosciences, a startup hoping to use the trillions of microbes in and on the human body to fight disease, is
READ MORECAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of
READ MOREEvelo currently has five product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis,
READ MORECAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine with systemic effects, today announced preclinical data for EDP1908, its extracellular vesicle product candidate for the
READ MOREEvelo Biosciences shares are trading higher after the company announced a $25.5 million private placement. July 10, 2023 | marketwatch . Evelo Biosciences Shares Rise 20% After Private Offering Prices. July 10, 2023 | msn . Evelo Biosciences Plans $25.5M Private Placement To Fund Psoriasis Trial, Pay Down Debt.
READ MOREEvelo Biosciences sets terms for IPO, to offer 5.3 mln shares priced at $15 to $17. Apr. 30, 2018 at 6:54 a.m. ET by Ciara Linnane. Other News. Press Releases.
READ MORECAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights
READ MORECAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo" or the "Company"), a clinical stage biotechnology company
READ MOREThe reverse stock split will become effective at 5:00 p.m. Eastern Time today, June 29, 2023, after close of trading on The Nasdaq Global Select Market. The Company''s common stock is expected to
READ MOREEvelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to
READ MORECAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced it has entered into a senior secured loan agreement with Horizon Technology Finance
READ MORECAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m.
READ MORECAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today presented preclinical data for EDP1867, a non-live pharmaceutical preparation of a single strain of
READ MORECAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company
READ MORECAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with
READ MORESpencer Platt via Getty Images. Evelo Biosciences, a biotechnology company launched by Flagship Pioneering to develop microbiome drugs, is shutting down, according to a regulatory filing. The move follows setbacks for the company, which was testing its lead drug candidate for inflammatory skin conditions. That drug failed the main
READ MOREThe data show that orally administered EDP1867 reduced disease severity and incidence of relapse in relapsing-remitting experimental autoimmune
READ MOREEvelo Biosciences, Inc. (EVLO) OTC Markets EXMKT - OTC Markets EXMKT Delayed price. Currency in USD. Find the latest Evelo Biosciences, Inc. (EVLO) stock quote, history, news and other vital information to help you with your stock trading and investing.
READ MORE